Skip to content

NASDAQ · mid · thesis board

NTLA Intellia Therapeutics

In vivo CRISPR (nexiguran / NTLA-2001 franchise)

View race

Thesis

Editorial summary — not a primary filing

In vivo CRISPR leader with ATTR program; pivotal path and safety are gates.

Next gate

2026-10-30Company-guidedPh3 readout

Pivotal ATTR update

78 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~14 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~517d)100%
Days to gate (78d)15%
Show math

$850M cash ÷ $50M/mo burn ≈ 517 days. Source: curated SEC quarter figures.

Cash $850M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
CRSPPh1okBEAMPh1okVERVPh1ok

Risks

  • Pivotal design
  • Delivery safety
  • Competition from Beam/Verve
  • Capital

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT06128629as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01